Assertio Holdings

Assertio Holdings, Inc. is a specialty pharmaceutical company based in Lake Forest, Illinois, focused on developing and commercializing products aimed at treating pain and central nervous system conditions. Founded in 1995, the company offers several FDA-approved products, including CAMBIA, an NSAID for migraine treatment; Zipsor, an NSAID for mild to moderate acute pain relief; Gralise, a gabapentin formulation for postherpetic neuralgia management; and NUCYNTA, available in both extended-release and immediate-release forms for managing neuropathic and moderate to severe acute pain. Assertio has established a strong market presence by leveraging innovative technologies and forming partnerships, such as its collaboration with Ironwood Pharmaceuticals. In May 2020, the company rebranded from Assertio Therapeutics to Assertio Holdings.

Brendan O'Grady

CEO and Board Member

Daniel Peisert

President, CEO and Director

2 past transactions

Spectrum Pharmaceuticals

Acquisition in 2023
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company based in Henderson, Nevada, specializing in the development and commercialization of innovative oncology and hematology drug products. Founded in 1987, the company is focused on acquiring and advancing targeted therapies, with notable candidates in its pipeline including ROLONTIS, a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, and Poziotinib, an irreversible tyrosine kinase inhibitor for non-small cell lung cancer with specific mutations. Additionally, Spectrum is developing an antibody-interferon fusion molecule aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. The company has established various collaborations, including agreements with Hanmi Pharmaceutical Co. Ltd. and The University of Texas M.D. Anderson Cancer Center, to enhance its research and development efforts. Spectrum Pharmaceuticals was formerly known as NeoTherapeutics, Inc. before rebranding in December 2002.

LGS Foundation

Grant in 2023
LGS Foundation is committed to enhancing the lives of people affected with LGS by promoting research, awareness, education, and family support.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.